Save the Date: Boston Will Become a Meeting Place for the Future of GI Oncology
10 Must-Read Posts in GU Oncology This Week
Marina Chiara Garassino Highlights Five-Year Follow-Up Results From the KEYNOTE-671 Trial in Resectable NSCLC
Lived Experience Advocacy Hub Webinar Opportunity: AI in Oncology
Adagene Completes Phase 2 Enrollment for Muzastotug Plus Pembrolizumab in MSS Colorectal Cancer
Kevin Donaghy: When Stage IV Melanoma Changed the Meaning of Hope
Amer Zeidan: Can All-Oral Therapy Reduce the Healthcare Burden for AML Patients?
10 Cancer Research Funding Opportunities to Know This November
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
